Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

por Diener, Hans-Christoph, Ashina, Messoud, Ritter, Shannon, Paiva Da Silva Lima, Gabriel, Rasmussen, Soeren, Zielman, Ronald, Tfelt-Hansen, Peer
Publicado 2021

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials

por Ashina, Messoud, Goadsby, Peter J., Dodick, David W., Tepper, Stewart J., Xue, Fei, Zhang, Feng, Brennan, Francis, Paiva da Silva Lima, Gabriel
Publicado 2021

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

por Ashina, Messoud, Goadsby, Peter J., Reuter, Uwe, Silberstein, Stephen, Dodick, David W., Xue, Fei, Zhang, Feng, Paiva da Silva Lima, Gabriel, Cheng, Sunfa, Mikol, Daniel D.
Publicado 2021

Timing and durability of response to erenumab in patients with chronic migraine

por Tepper, Stewart J., Lucas, Sylvia, Ashina, Messoud, Schwedt, Todd J., Ailani, Jessica, Scanlon, James, Klatt, Jan, Chou, Denise E., Wang, Andrea, Paiva da Silva Lima, Gabriel
Publicado 2021

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

por Ferrari, Michel Dominique, Reuter, Uwe, Goadsby, Peter J, Paiva da Silva Lima, Gabriel, Mondal, Subhayan, Wen, Shihua, Tenenbaum, Nadia, Pandhi, Shaloo, Lanteri-Minet, Michel, Stites, Tracy
Publicado 2022

Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study

por Goadsby, Peter J., Reuter, Uwe, Lanteri-Minet, Michel, Paiva da Silva Lima, Gabriel, Hours-Zesiger, Peggy, Fernandes, Chrystel, Wen, Shihua, Tenenbaum, Nadia, Kataria, Aditi, Ferrari, Michel D., Klatt, Jan
Publicado 2021